Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has shared an announcement.
Shanghai Fosun Pharmaceutical’s subsidiary, Shanghai MicroH Therapeutics, has received approval from the US FDA to commence a Phase I clinical trial for LBP-ShC4, a live biotherapeutic product aimed at treating androgenetic alopecia. This approval marks a significant step as no live biotherapeutic product has been approved globally for this condition, highlighting the company’s potential impact on the market and its commitment to innovative healthcare solutions.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock limited company based in China, operating in the pharmaceutical industry. The company focuses on the development and production of pharmaceutical products, with a market emphasis on innovative drug development and healthcare services.
Average Trading Volume: 5,778,567
Technical Sentiment Signal: Sell
Current Market Cap: HK$61.89B
Learn more about 2196 stock on TipRanks’ Stock Analysis page.